Le traitement prophylactique par dexaméthasone réduit les réactions liées à la perfusion chez les patients atteints d'un cancer du poumon non à petites cellules avancé muté EGFR et traités par RYBREVANT® ▼ (amivantamab) par voie intraveineu
September 13, 2024 12:09 ET
|
Janssen Cilag International NV
La prémédication à une dose de 8 mg à entraîné un taux de réaction lié à la perfusion de 22,5 pour cent avec l'amivantamab par voie intraveineuse, soit trois fois moins que le taux de 67,4 pour cent...
RYBREVANT®▼ (amivantamab) en association avec le lazertinib montre une tendance très favorable en matière de survie globale par rapport à l'osimertinib dans le cancer du poumon non à petites cellules avancé muté par l’EGFR
September 11, 2024 06:09 ET
|
Janssen Cilag International NV
De nouvelles données à plus long terme issues de l'étude MARIPOSA confirment les résultats supérieurs de l'association amivantamab plus lazertinib par rapport à l'osimertinib en monothérapie en tant...
Prophylactic dexamethasone regimen reduces infusion-related reactions in patients with EGFR-mutated advanced non-small cell lung cancer treated with intravenous RYBREVANT®▼ (amivantamab)
September 10, 2024 18:20 ET
|
Janssen Cilag International NV
The 8 mg pre-medication regimen showed an infusion-related reaction rate of 22.5 percent with intravenous amivantamab, a three-fold reduction from 67.4 percent historically seen with standard IRR...
RYBREVANT®▼ (Amivantamab) plus Lazertinib zeigen einen starken positiven Trend beim Gesamtüberleben im Vergleich zu Osimertinib bei EGFR-mutiertem fortgeschrittenem Lungenkrebs
September 10, 2024 13:04 ET
|
Janssen Cilag International NV
Neue Langzeitdaten aus der MARIPOSA-Studie bestätigen die überlegenen Ergebnisse der lazertinib-plus-lazertinib-Therapie im Vergleich zur Osimertinib-Monotherapie als Erstlinientherapie1 Ergebnisse...
Libtayo® (cemiplimab) Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer
September 09, 2024 17:00 ET
|
Regeneron Pharmaceuticals, Inc.
Late-breaking data at WCLC show Libtayo monotherapy nearly doubled median overall survival and reduced the risks of death and disease progression by 41% and 50%, respectively, compared to chemotherapy...
Boehringer’s zongertinib shows encouraging efficacy and tolerability profile in previously treated HER2 mutated lung cancer patients
September 09, 2024 11:45 ET
|
Boehringer Ingelheim
Beamion LUNG-1, Phase Ib met its primary endpoint, demonstrating a meaningful objective response rate (ORR) of 66.7%, as assessed by blinded independent central review (BICR)1Preliminary activity in...
Regeneron to Highlight Progress Across Its Differentiated Oncology Portfolio and Pipeline at WCLC and ESMO
September 09, 2024 07:00 ET
|
Regeneron Pharmaceuticals, Inc.
At WCLC, five-year survival data to be presented on Libtayo (PD-1 inhibitor) first-line monotherapy in advanced non-small cell lung cancer At ESMO, longer-term results with investigational fianlimab...
RYBREVANT®▼ (amivantamab) plus lazertinib show strong favourable overall survival trend versus osimertinib in EGFR-mutated advanced lung cancer
September 08, 2024 14:30 ET
|
Janssen Cilag International NV
New longer-term data from the MARIPOSA study confirm superior outcomes of amivantamab plus lazertinib regimen compared to osimertinib monotherapy as first-line therapy1 ...
Boehringer Ingelheim to unveil groundbreaking oncology research at WCLC, demonstrating strength of portfolio
August 27, 2024 03:05 ET
|
Boehringer Ingelheim
Data from the phase Ib Beamion LUNG-1 trial selected for late-breaking oral presentation in the Presidential Symposium at WCLC on Monday, September 9. The U.S. FDA and China's CDE have granted...
SciSparc: MitoCareX Appointed Professor Nir Peled, Seasoned Oncologist, to its Scientific Advisory Board
August 22, 2024 08:12 ET
|
SciSparc Ltd
Professor Peled is the Director of the Oncology Department at the Shaare Zedek Medical Center, Jerusalem, Israel, and the head of the Global Multidisciplinary Practice Standards Committee (GMPSC) of...